TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a first-person essay published by Being Patient on October 6, 2026, Ron Carr describes three health notifications that changed how he viewed Alzheimer’s risk and prevention. The supplied excerpt details his discovery of two APOE4 copies and coronary artery plaque; it does not include the third notification or establish that his genetic result predicts he will develop Alzheimer’s.
Ron Carr’s first two health notifications—a genetic test showing two copies of APOE4 and a scan revealing coronary artery plaque—prompted the patient advocate to rethink his Alzheimer’s risk and health decisions, according to a first-person account published by Being Patient on October 6, 2026. The supplied article excerpt describes those findings but ends before explaining the third notification.
Carr writes that he learned of his APOE4 status two years before the article was published. He initially experienced the result as a prediction, saying he began treating everyday lapses, such as forgetting a name or misplacing keys, as possible signs of future disease. He responded by reading research and changing his diet, exercise routine and supplements. He also describes using prescription sleeping pills that left him groggy and irritable.
Over time, Carr says, he came to understand APOE4 as a risk factor, not a diagnosis. He writes that this changed his view of genetic testing: instead of treating it as a forecast, he began thinking of it as information that could guide decisions. The essay does not report that Carr has Alzheimer’s disease or provide a clinical assessment of his personal chance of developing it.
The second notification followed a coronary artery calcium scan, which Carr says he received after discussing APOE4 with a clinician at USC. Although he felt healthy and had a cholesterol level his physician had considered acceptable, the scan showed calcified plaque concentrated mainly in his left anterior descending artery. Carr says he was diagnosed with atherosclerotic cardiovascular disease at age 65. He reports that his clinician then lowered his LDL cholesterol and ApoB targets; follow-up testing found no evidence of structural heart damage.
How Genetic Risk Changed His Choices
Carr’s account illustrates how a health finding can affect both medical discussions and emotional wellbeing. A genetic risk result led him to monitor ordinary memory slips and try multiple lifestyle changes; later, a scan identified cardiovascular disease despite his feeling well. He says the scan shifted his attention from an inherited risk to a condition his clinician could address directly.
The story is a personal account, not evidence that APOE4 testing or calcium scans should be used in the same way for everyone. Carr’s experience also does not establish that treating cardiovascular risk will prevent Alzheimer’s. Its relevance is that it shows how risk information can shape a patient’s decisions and conversations with clinicians—and why a genetic result should not be confused with a diagnosis.
genetic testing kits for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From APOE4 Result to Heart Scan
Carr identifies himself as a retired local government executive and patient advocate whose work focuses on Alzheimer’s prevention, genetic testing and cardiovascular health. The Being Patient article presents his experience in the first person. He says his father had a heart attack at 65, a family history that influenced Carr’s long-standing efforts to protect his heart, including distance running, a heart-conscious diet and eventually statin therapy.
In the essay, Carr says his understanding of APOE4 expanded beyond Alzheimer’s risk after a USC clinician discussed its role in lipid transport. That discussion preceded his calcium scan. The article also cites a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That figure is an estimate about dementia cases broadly, as reported in Carr’s essay; it is not a measure of how much an individual can lower personal Alzheimer’s risk.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in his Being Patient essay
As an affiliate, we earn on qualifying purchases.
The Third Notification Is Missing
The supplied source text stops partway through Carr’s account of the heart scan and does not identify the third notification promised in the headline. It is therefore unclear what that notification was, when it arrived, or what effect it had. The excerpt also does not provide Carr’s scan measurements, the details of his treatment, or evidence that his experience applies to other people with APOE4.
The account does not say that Carr has Alzheimer’s or that his genetic result makes the disease inevitable. Individual risk and care decisions require clinical context; the article excerpt does not supply a personalized risk estimate or establish a prevention outcome.
LDL cholesterol lowering supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Full Account May Add
The next step for readers seeking the complete story is to consult the full Being Patient article, which may contain the portion missing from the supplied excerpt and explain Carr’s third notification. No future test, treatment milestone or follow-up announcement is identified in the material provided.
Carr’s account describes his own discussions with clinicians and changes in care after a scan. Readers should not treat those choices as medical instructions: people considering genetic testing, cardiovascular screening or changes to medication can discuss their individual circumstances with a qualified health professional.
As an affiliate, we earn on qualifying purchases.
Key Questions
What were the two notifications described in the excerpt?
Carr says genetic testing showed he had two copies of APOE4. A later coronary artery calcium scan showed calcified plaque in his coronary arteries.
Does having two copies of APOE4 mean someone has Alzheimer’s?
No. Carr describes APOE4 as a risk factor, not a diagnosis. His essay does not report that he has Alzheimer’s, and the excerpt gives no individual prediction of whether he will develop it.
What did Carr’s heart scan show?
Carr says it found significant calcified plaque, concentrated mainly in the left anterior descending artery. He reports that his clinician diagnosed atherosclerotic cardiovascular disease and adjusted his LDL cholesterol and ApoB targets.
What was the third health notification?
The supplied excerpt does not say. Although the headline refers to three notifications, the text provided ends during the discussion of Carr’s heart scan.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
